首页> 外国专利> TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FAMPRIDINE.

TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FAMPRIDINE.

机译:拉喹莫德和氟哌丁胺联合治疗多发性硬化症。

摘要

This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject fampridine as an add-on therapy to or in combination with laquinimod. This invention also provides a package comprising laquinimod and fampridine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides fampridine for use as an add-on therapy or in combination with laquinimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and fampridine for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fampridine in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
机译:本发明提供了一种治疗患有多发性硬化症或表现出临床分离的综合症的受试者的方法,该方法包括向该受试者施用氟哌啶作为拉喹莫德的附加疗法或与拉喹莫德组合。本发明还提供了包含拉喹莫德和氟哌啶的包装,用于治疗患有多发性硬化症或表现出临床分离的综合症的受试者。本发明还提供了用作补充疗法或与拉喹莫德组合的甲氨蝶呤,用于治疗患有多发性硬化症或表现出临床分离的综合症的受试者。本发明还提供了包含拉喹莫德和氟哌啶的药物组合物,用于治疗患有多发性硬化症或表现出临床分离的综合症的受试者。本发明进一步提供了拉喹莫德和氟哌啶在制备用于治疗患有多发性硬化症或表现出临床分离的综合征的受试者的组合中的用途。

著录项

  • 公开/公告号MX2015000485A

    专利类型

  • 公开/公告日2015-04-08

    原文格式PDF

  • 申请/专利权人 TEVA PHARMACEUTICAL INDUSTRIES LTD.;

    申请/专利号MX20150000485

  • 发明设计人 NORA TARCIC;JOEL KAYE;

    申请日2013-07-11

  • 分类号A61P25/02;A01N43/42;A01N45;

  • 国家 MX

  • 入库时间 2022-08-21 15:13:52

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号